Professor Olli Kallioniemi is former Director of the Institute of Molecular Medicine Finland (FIMM). He oversaw the growth of FIMM to a leading national and international research center, which makes up the Finnish part of the Nordic EMBL Partnership. He is currently Director of SciLifeLab in Stockholm and a Professor at the Karolinska Institute.
Career to date
Professor Kallioniemi’s broad experience, spanning from biotechnology, proteomics and high throughput biology to systems medicine and systems pharmacology made him the perfect choice for the NCMM SAB.
Commenting on the appointment, Director of NCMM Professor Kjetil Taskén said, ‘We are delighted to appoint Olli to the SAB. His background and experience made him the ideal candidate, and we’re very much looking forward to working with him.’
After receiving his M.D. and Ph.D. at the University of Tampere, Finland, Professor Kallioniemi continued his career at UC San Francisco and was appointed faculty at the National Human Genome Research Institute, at the NIH, USA. He also founded and developed the Medical Biotechnology group at the University of Turku, together with the VTT Technical Research Centre, Finland.
Research interests
Professor Kallioniemi’s research interests span cancer biology and genomics, molecular pathology and translational research, high-throughput technology development and data analysis. He is also a strong propagator for P4 medicine: Predictive, Preventive, Personalized and Participatory health care.